Product Description
50 mg Bicalutamide Tablets IP are the ones is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate. 50 mg Bicalutamide Tablets IP are minutely tested on diverse parameters before the final dispatching from our unit.